Qalabka tijaabada degdega ah ee SARS-CoV-2 Antigen
Sharaxaad Gaaban:
SARS-CoV-2 Antigen Rapid Cassette waa immunoassay chromatographic degdeg ah oo loogu talagalay ogaanshaha tayada ee SARS-CoV-2 antigen ee swabs Oropharyngeal ee bini'aadamka. Aqoonsigu wuxuu ku salaysan yahay unugyada unugyada monoclonal ee gaarka ah ee borotiinka Nucleocapsid (N) borotiinka SARS- CoV-2. Waxaa loogu talagalay in lagu caawiyo ogaanshaha degdegga ah ee kala duwanaanshaha caabuqa COVID-19.
ISTICMAALKA KULA JIRA
TheQalabka tijaabada degdega ah ee SARS-CoV-2 Antigenwaa immunoassay chromatographic degdeg ah oo loogu talagalay ogaanshaha tayada SARS-CoV-2 antigen ee bini'aadamka Oropharyngeal swabs. Aqoonsigu wuxuu ku salaysan yahay unugyada unugyada monoclonal ee u gaarka ah Nucleocapsid (N) Protein ee SARS-CoV-2. Waxaa loogu talagalay in lagu caawiyo ogaanshaha kala duwanaanshaha degdega ah eeCOVID 19caabuq.
Tilmaamaha Xidhmada
25 tijaabooyin/xirmo, 50 imtixaan/xirmo, 100 imtixaan/xirmo
HORDHAC
Fayraska novel wuxuu ka tirsan yahay genus β.COVID 19Hadda, bukaannada uu ku dhacay novel coronavirus ayaa ah isha ugu weyn ee caabuqa; dadka asymptomatic-ka qaba waxay sidoo kale noqon karaan ilo faafa ilaa 14 maalmood, inta badan 3 ilaa 7 maalmood. Calaamadaha ugu waaweyn waxaa ka mid ah qandho, daal iyo qufac qalalan. Sanka oo xidhmo, diif, cune xanuun, myalgia iyo shuban ayaa laga helaa dhowr xaaladood.
REAGENTS
Cajalada tijaabada ah waxay ka kooban tahay anti-SARS-CoV-2 Qaybaha borotiinka Nucleocapsid iyo anti-SARS-CoV-2 borotiinka Nucleocapsid ee ku dahaaran xuubka.
KA TAXADARITAAN
Fadlan akhri dhammaan macluumaadka ku jira xidhmadan ka hor inta aanad samaynin tijaabada.
1. Loogu talagalay xirfadlayaasha in vitro ogaanshaha isticmaalka kaliya. Ha isticmaalin ka dib taariikhda dhicitaanka.
2. Tijaabadu waa in ay ku sii jirtaa jeebka xidhan ilaa inta uu diyaar u yahay in la isticmaalo.
3. Dhammaan shaybaarrada waa in loo tixgeliyo inay yihiin kuwo khatar ah oo loo maareeyo si la mid ah wakiilka caabuqa.
4. Tijaabada la isticmaalay waa in la tuuraa si waafaqsan xeerarka deegaanka.
5.Ka fogow isticmaalka muunado dhiig leh.
6. Xidho galoofyada wen wareejinta shaybaarada, ka fogow taabashada xuubka reagent iyo muunad si fiican.
Kaydinta iyo Xasiloonida
Muddada ansaxnimadu waa 18 bilood haddii alaabtan lagu kaydiyo deegaan
2-30℃. Tijaabadu waa mid xasiloon ilaa taariikhda uu dhacayo ee lagu daabacay boorsada xidhan..Ha barafaysan.Ha isticmaalin wixii ka dambeeya taariikhda dhicitaanka.
URURINTA IYO DIYAARINTA NUSOOYINKA
1.Ururinta dheecaanka dhuunta: Geli suufka nadiifka ah ee dhuunta gabi ahaanba ka soo baxa afka, adigoo udub dhexaad u ah gidaarka dhuunta iyo meesha guduudan ee qumanka saxarada, masax qumanka pharyngeal ee laba geesoodka ah iyo gidaarka pharyngeal dambe oo dhexdhexaad ah
xoog, iska ilaali taabashada carrabka oo ka saar suufka.
2. Isla markiiba muunada ku samee xalka muunada soo saarista ee lagu soo dhex riday qalabka ka dib marka muunada la qaado. Haddii aan si dhakhso ah loo farsamayn karin, muunadda waa in lagu kaydiyaa tuubo qallalan, jeermis dilay oo si adag loo xidhay. Waxaa lagu kaydin karaa at 2-8 ℃ 8 saacadood, oo waxaa lagu kaydin karaa waqti dheer at -70 ℃.
3. Muunado ay si aad ah u wasakhaysan yihiin hadhaaga cuntada afka looma isticmaali karo tijaabada alaabtan. Tijaabooyin laga soo ururiyay suufka aadka u muuqda ama kacsan laguma talinayo in lagu tijaabiyo alaabtan. Haddii suufku ay ku wasakhoobeen xaddi badan oo dhiig ah, laguma talinayo in la baaro. Laguma talinayo in la isticmaalo shaybaarada lagu farsameeyay xal muunad soo saarid ah oo aan lagu bixin qalabkan si loogu tijaabiyo alaabtan.
QAYBAHA KIT
Qalabka ayaa bixiya
Tijaabi cajaladaha | Soo saarista Reagent | Tuubooyinka soo saarista | |
Madhalaysnimo | Gelida Xidhmada | Goobta Shaqada |
Alaabta loo baahan yahay laakiin lama bixiyo
Saacadaha | Isticmaalka wakhtiga. |
Xidhmada |
Tilmaamaha25
imtixaanada/pack50
imtixaanada/pack100
Tijaabooyin/xirmoSample Extraction Reagent25 tests/pack50 tests/pack100 tests/packSample Extraction
tube≥25 imtixaanada/xirmo≥50 imtixaanada/xirmo≥100 imtixaanada/xirmada tixraac
xirmo tixraac
xirmo tixraac
xirmo
Tilmaamaha Isticmaalka
Oggolow tijaabada, muunada, kaydinta soo saarista inay u dhigmaan heerkulka qolka (15-30℃) ka hor baaritaanka.
1. Ka saar cajaladda tijaabada ah shandad foornada xidhan oo isticmaal 15 daqiiqo gudahood. Natiijooyinka ugu fiican ayaa la heli doonaa haddii baaritaanka la sameeyo isla markiiba ka dib marka la furo boorsada qashinka.
2. Dhig tuubada soo saarista goobta shaqada Tube.
3. Geli muunada suufka tuubada soo saarida
4. Ka saar suufka markaad madaxa suufka ku tuujinayso gudaha tuubada soo saarista markaad ka saarto si aad u soo saarto dareeraha ugu badan ee suurtogalka ah u samee suufka. Tuur suufka si waafaqsan nidaamka qashin-saarka biohazard-ka.
5.Ku hafi caarada dhibcaha ee dusheeda tuubada soo saarista. Dhig cajaladda tijaabada dusha nadiif ah oo siman.
6.Ku dar 2 dhibcood oo xalka ah (qiyaastii,65μL) muunada si fiican ka dibna billow saacada. Akhri natiijada la soo bandhigay 20-30 daqiiqo gudahood, natiijadii la akhriyay 30 daqiiqo ka dib waa sax.
FARSAMADA NATIIJADA
NEGTIVE NATIIJO: |
Hal xariiq oo midab leh ayaa ka muuqda gobolka khadka kantaroolka (C). Ma jiro wax khad ah oo ka soo baxaya gobolka tijaabada (T).Natiijada taban waxay muujinaysaa in antigen-ka SARS-CoV-2 aanu ku jirin muunadda, ama uu ka hooseeyo heerka la ogaan karo ee baadhista.
TOGANNATIIJO:
Laba xariiq ayaa soo muuqda.hal xarriiq oo midab leh waa inuu ku yaal gobolka kantaroolka (C) iyo khad kale oo midab leh oo muuqda waa inuu ku yaal gobolka tijaabada (T) Natiijadu waxay muujineysaa in SARS-CoV-2 laga helay muunada.
NATIIJO AAN AHAYN:
Khadka kantaroolku wuu soo bixi waayay Dib u eeg nidaamka oo ku celi tijaabada imtixaan cusub. Haddii dhibaatadu sii socoto, jooji isticmaalka qalabka tijaabada isla markiiba oo la xidhiidh qaybiyaha xaafaddaada.
FIIRO GAAR AH:
Xoogagga midabka gobolka khadka tijaabada (T) wuu kala duwanaan doonaa iyadoo kuxiran fiirsashada SARS-CoV-2 Antigen ee ku jirta muunada. Sidaa darteed, hadh kasta oo midab ah oo ku yaal gobolka khadka tijaabada (T) waa in loo tixgeliyaa mid wanaagsan.
Kontaroolka tayada
- Xakamaynta habraaca ayaa ku jirta imtixaanka. Xariiq midab leh oo ka soo muuqda gobolka kantaroolka (C) waxaa loo tixgeliyaa kontorool habraac gudaha ah.Waxay xaqiijinaysaa xuubka ku filan.
- Heerarka xakamaynta lama bixiyo xirmadan; si kastaba ha ahaatee, waxaa lagu talinayaa in kontaroolada togan iyo kuwa taban la tijaabiyo si ay u noqdaan dhaqan shaybaar oo wanaagsan si loo xaqiijiyo nidaamka tijaabada iyo si loo xaqiijiyo waxqabadka saxda ah ee imtixaanka.
XADKAEE IMTIXAANKA
- Cassette-ka SARS-CoV-2 Antigen Degdegga ah ee Tijaabada degdegga ah waxaa loogu talagalay xirfad-yaqaannada isticmaalka ogaanshaha fayraska oo keliya. Tijaabada waa in loo adeegsadaa ogaanshaha SARS-CoV-2 Antigen ee Oropharyngeal Swab. Qiimaha tirada iyo heerka korodhka SARS- midna ma aha. U fiirsashada CoV-2 waxaa lagu go'aamin karaa tijaabadan tayada leh.
- Saxnaanta imtixaanku waxay kuxirantahay tayada muunada suufka
- Cassette-ka SARS-CoV-2 Antigen Degdegga ah ee Tijaabada ayaa kaliya tilmaami doonta joogitaanka SARS-CoV-2 ee muunada ka yimid noocyada coronavirus-ka ee SARS-CoV-2 ee la hirgelin karo iyo kuwa aan macquul ahayn.
- Sida dhammaan baaritaanada ogaanshaha, dhammaan natiijooyinka waa in lala tarjumaa macluumaadka kale ee caafimaad ee uu heli karo takhtarka.
- Natiijo taban oo laga helay xirmadan waa in ay xaqiijiso PCR. Natiijooyin taban ayaa laga yaabaa in la helo haddii xoogga saaridda SARS-CoV-2 ee ku jirta suufka aysan ku filneyn ama ay ka hooseyso heerka la ogaan karo ee baaritaanka.
- Dhiiga xad-dhaafka ah ama xababka ku jira shaybaarka suufka ayaa laga yaabaa inay farageliyaan waxqabadka waxaana laga yaabaa inay keenaan natiijo wanaagsan oo been ah.
- Natiijooyinka togan ee SARS-CoV-2 kama reebayso infekshan hoose oo leh cudur-sidaha kale. Sidaa darteed, suurtogalnimada infekshanka bakteeriyada ee aan qarsoonayn waa in la tixgeliyaa.
- Natiijooyinka taban kama saarayaan infekshanka SARS-CoV-2, gaar ahaan kuwa la xiriira fayraska. Baaritaanka daba-galka ah ee baaritaanka molecular waa in la tixgeliyo si meesha looga saaro infekshanka shakhsiyaadkan.
- Natiijooyinka wanaagsan ayaa laga yaabaa inay sabab u tahay infekshanka jira noocyada aan ahayn SARS-CoV-2 ee coronavirus, sida coronavirus HKU1, NL63, OC43, ama 229E.
- Natiijooyinka ka soo baxa baaritaanka antigen-ka waa in aan loo isticmaalin saldhigga kaliya si loo baaro ama looga saaro caabuqa SARS-CoV-2 ama in lagu wargeliyo heerka caabuqa.
- Dareeraha soo saarista ayaa awood u leh in uu dilo fayraska, laakiin ma dami karo 100% fayraska. Habka hawl-gabka fayraska waxaa loo tixraaci karaa: habka ay ku taliso WHO/CDC, ama waxaa loo maarayn karaa si waafaqsan xeerarka maxalliga ah.
Tilmaamaha Waxqabadka
DareenkaiyoGaar ahaan
Qalabka tijaabada degdega ah ee SARS-CoV-2 Antigen-ka ayaa lagu qiimeeyay muunado laga helay bukaanada.PCR waxa loo isticmaalaa habka tixraaca ee SARS-CoV-2 Antigen Rapid Cassette. Tijaabooyin ayaa loo tixgaliyay inay wanaagsan yihiin haddii PCR ay muujiso natiijo togan.
Habka | RT-PCR | Wadarta Natiijooyinka | ||
Qalabka tijaabada degdega ah ee SARS-CoV-2 Antigen | Natiijooyinka | Wanagsan | xun | |
Wanagsan | 38 | 3 | 41 | |
xun | 2 | 360 | 362 | |
Wadarta Natiijooyinka | 40 | 363 | 403 |
Dareenka Qaraabada :95.0%(95%CI*:83.1%-99.4%)
Gaar ahaan Qaraabada:99.2%(95%CI*:97.6%-99.8%)
* Kalsoonida Dhexdeeda
Xadka ogaanshaha
Marka fayrasku ka kooban yahay 400TCID50/ml, heerka ogaanshaha togan ayaa ka weyn 95%. Marka fayrasku ka kooban yahay 200TCID50/ml, heerka ogaanshaha togan waxa uu ka yar yahay 95%, markaa xadka ogaanshaha ugu yar ee alaabtani waa 400TCID50/ml.
Saxnaanta
Saddex qaybood oo isku xigta oo reagents ah ayaa la tijaabiyey inay sax yihiin. Qaybo kala duwan oo reagents ah ayaa loo isticmaalay in lagu tijaabiyo isla muunad taban 10 jeer oo isku xigta, natiijaduna waxay ahaayeen dhamaantood diidmo. Qaybo kala duwan oo reagen ah ayaa loo isticmaalay in lagu tijaabiyo muunado togan oo isku mid ah 10 jeer oo isku xigta, natiijaduna waxay ahaayeen dhamaantood togan.
Saamaynta HOOK
Marka waxa fayraska ku jira muunada la tijaabinayo uu gaadho 4.0*105TCID50/ml, natiijadu wali ma muujinayso saamaynta HOOK.
Falcelinta-celinta
Falcelinta-celinta-celinta ee Qalabka ayaa la qiimeeyay. Natiijadu ma muujin falcelin isdhaafsi ah oo la socda muunadaha soo socda.
Magaca | Xoog-saarid |
HCOV-HKU1 | 105TCID50/ml |
Staphylococcus aureus | 106TCID50/ml |
Kooxda A streptococci | 106TCID50/ml |
Fayraska jadeecada | 105TCID50/ml |
Fayraska qaamo-qashiirta | 105TCID50/ml |
Adenovirus nooca 3 | 105TCID50/ml |
Mycoplasmal pneumonia | 106TCID50/ml |
Paraimfluenzavirus, nooca 2 | 105TCID50/ml |
Metapneumovirus aadanaha | 105TCID50/ml |
Coronavirus-ka aadanaha OC43 | 105TCID50/ml |
Coronavirus-ka aadanaha 229E | 105TCID50/ml |
Bordetella parapertosis | 106TCID50/ml |
Hargabka B Victoria STRAIN | 105TCID50/ml |
Hargabka B YSTRAIN | 105TCID50/ml |
Hargabka A H1N1 2009 | 105TCID50/ml |
Hargabka A H3N2 | 105TCID50/ml |
H7N9 | 105TCID50/ml |
H5N1 | 105TCID50/ml |
Fayraska Epstein-Barr | 105TCID50/ml |
Enterovirus CA16 | 105TCID50/ml |
Rhinovirus | 105TCID50/ml |
Fayruuska unugyada neefsasha | 105TCID50/ml |
Streptococcus pneumoni-ae | 106TCID50/ml |
Candida albicans | 106TCID50/ml |
Chlamydia oof wareen | 106TCID50/ml |
Bordetella xiiq-dheerta | 106TCID50/ml |
Pneumocystis jiruveci | 106TCID50/ml |
Mycobacterium tuberku-losis | 106TCID50/ml |
Legionella pneumophila | 106TCID50/ml |
IWalxaha farageliya
Natiijooyinka baaritaanka laguma faragelin walaxda marka la eego xoogga soo socda:
Faragelin walax | Conc. | Walaxda faragelinaysa | Conc. |
Dhiig dhan | 4% | Isku-darka Benzoin Gel | 1.5mg/ml |
Ibuprofen | 1mg/ml | Cromolyn glycate | 15% |
tetracycline | 3ug/ml | chloramphenicol | 3ug/ml |
Mucin | 0.5% | Mupirocin | 10mg/ml |
Erythromycin | 3ug/ml | Oseltamivir | 5mg/ml |
Tobramycin | 5% | Naphazoline Hydrochlo- raacida Dhibcaha Sanka | 15% |
menthol | 15% | Fluticasone propionate buufin | 15% |
Afrin | 15% | Deoxyepinephrine hydro-chloride | 15% |
IBBLIOGRAPHY
1.Weiss SR,Leibowitz JZ. Cudurka Coronavirus. Adv Virus Res 2011;81:85-164
2.Cui J,Li F,Shi ZL.Asal ahaan iyo koboca cudurka coronaviruses.
3.Su S, Wong G, Shi W, iyo al. Epidemiology, dib-u-habaynta hidda-socodka, iyo cudur-sidaha coronaviruses. TrendsMicrobiol 2016;24:490-502.